Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Cash from Operations (2023 - 2025)

Historic Cash from Operations for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$33.8 million.

  • Inhibrx Biosciences' Cash from Operations fell 1170.04% to -$33.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$143.4 million, marking a year-over-year increase of 3089.88%. This contributed to the annual value of -$194.4 million for FY2024, which is 56.9% down from last year.
  • Inhibrx Biosciences' Cash from Operations amounted to -$33.8 million in Q3 2025, which was down 1170.04% from -$30.0 million recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' Cash from Operations ranged from a high of -$30.0 million in Q2 2025 and a low of -$63.0 million during Q1 2024
  • For the 3-year period, Inhibrx Biosciences' Cash from Operations averaged around -$45.0 million, with its median value being -$43.7 million (2024).
  • The largest annual percentage gain for Inhibrx Biosciences' Cash from Operations in the last 5 years was 4777.89% (2025), contrasted with its biggest fall of 1170.04% (2025).
  • Quarter analysis of 3 years shows Inhibrx Biosciences' Cash from Operations stood at -$56.8 million in 2023, then grew by 23.06% to -$43.7 million in 2024, then increased by 22.63% to -$33.8 million in 2025.
  • Its Cash from Operations was -$33.8 million in Q3 2025, compared to -$30.0 million in Q2 2025 and -$35.9 million in Q1 2025.